NCT07336342

Brief Summary

The goal of this clinical trial is to pilot an adaptation of mindfulness-based cognitive therapy for chronic pain and depression. The main questions it aims to answer in a later fully powered randomized controlled trial are:

  • Is an adaptation of mindfulness-based cognitive therapy for older Black adults able to improve quality of life?
  • Will an adapted mindfulness based cognitive therapy reduce pain interference to a greater degree than a traditional health enhancement program?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable chronic-pain

Timeline
Completed

Started Nov 2024

Shorter than P25 for not_applicable chronic-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 15, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 22, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 22, 2025

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 8, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
Last Updated

January 13, 2026

Status Verified

September 1, 2025

Enrollment Period

8 months

First QC Date

January 8, 2026

Last Update Submit

January 10, 2026

Conditions

Keywords

mindfulness-based cognitive therapymind-bodychronic paindepressionolder adult

Outcome Measures

Primary Outcomes (3)

  • The Credibility and Expectancy Questionnaire

    This scale measures participant expectations around the study's positive outcomes, with measures ranging from 0 (not at all expected) to 9 (extremely expected). A higher score indicate greater trust in the study design and an openness to potential benefits.

    From enrollment to 3 months from the end of treatment at 8 weeks

  • The Client Satisfaction Questionnaire

    Three item scale measuring patient satisfaction with the program. Scores for each item range from 1 (unsatisfied) to 4 (very satisfied).

    Administered at the end of treatment at 8 weeks and at the three month follow up visit.

  • Modified Patient Global Impression of Change

    Measures participant impressions of overall change with one being very much improved and eight being very much worse. Lower scores indicate improvement.

    At end of 8 week program (post test) and again at 3 month follow up visit.

Secondary Outcomes (11)

  • Numerical Rating Scale

    From enrollment to 3 months from the end of treatment at 8 weeks.

  • PROMIS Physical Function

    From enrollment to 3 months from the end of treatment at 8 weeks

  • PROMIS Anxiety

    From enrollment to 3 months from the end of treatment at 8 weeks

  • PROMIS Depression

    From enrollment to 3 months from the end of treatment at 8 weeks

  • PROMIS Emotional Support

    From enrollment to 3 months from the end of treatment at 8 weeks.

  • +6 more secondary outcomes

Study Arms (1)

Quiet Focus

EXPERIMENTAL
Behavioral: Quiet Focus

Interventions

Quiet FocusBEHAVIORAL

Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression.

Quiet Focus

Eligibility Criteria

Age50 Years - 120 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Older adult (age ≥ 50)
  • All individuals who identify with one or more nationalities or ethnic groups originating in any of the Black racial groups of Africa
  • Pain in muscles, joints, bones, or associated soft tissues (NRS\>4) lasting longer than 3 months
  • Depressed (PHQ-9 score of 5-14)
  • English fluency/literacy
  • Ability and willingness to participate via in-person and video
  • No change to type or dose of antidepressant medications for at least 6 weeks prior to screening
  • Willing to provide informed consent and comply with all aspects of the protocol

You may not qualify if:

  • Moderately severe or severe depressive symptoms (PHQ-9 ≥ 15)
  • Current substance abuse/dependence
  • Significant cognitive impairment
  • History of more than 8 sessions of cognitive-behavioral therapy
  • History of previous training in mindfulness or undergoing counseling more than once a month
  • History of or current diagnosis of psychosis
  • Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening) or self-harm within the past 90 days
  • Current participation in another behavioral clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Chronic PainDepression

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehavior

Study Officials

  • Tony V Pham, MD, MScGH

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator and Psychiatrist

Study Record Dates

First Submitted

January 8, 2026

First Posted

January 13, 2026

Study Start

November 15, 2024

Primary Completion

July 22, 2025

Study Completion

July 22, 2025

Last Updated

January 13, 2026

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

All IPD collected throughout the trial.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE

Locations